Rybelsus is an FDA-approved prescription medication indicated for the treatment of Type 2 diabetes in adults. It is also used to reduce the risk of heart attack, stroke, and other cardiovascular events in adults with Type 2 diabetes who also have established heart disease.
The active ingredient in Rybelsus is semaglutide, which is a member of the GLP-1 receptor agonist drug class. Unlike other GLP-1 medications, Rybelsus contains a special absorption helper called salcaprozate sodium (SNAC), which temporarily changes the stomach environment and helps semaglutide pass through the stomach lining and into the bloodstream.
